- Home
- PBFS vs AVIR Comparison
PBFS vs AVIR Comparison
Compare PBFS & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBFS | AVIR |
|---|---|---|
| Founded | 1889 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.2M | 429.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PBFS | AVIR |
|---|---|---|
| Price | $17.94 | $5.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 11.9K | ★ 247.6K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.07 | 3.00 |
| EPS | ★ 0.36 | N/A |
| Revenue | $15,814,000.00 | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $49.14 | ★ N/A |
| Revenue Growth | ★ 5.76 | N/A |
| 52 Week Low | $12.64 | $2.78 |
| 52 Week High | $19.91 | $6.45 |
Technical Indicators
Market Signals| Indicator | PBFS | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 44.81 |
| Support Level | $16.73 | $5.01 |
| Resistance Level | $18.33 | $5.76 |
| Average True Range (ATR) | 0.54 | 0.21 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 30.58 | 16.79 |
Price Performance
Historical ComparisonAbout PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.